Stock comparison
Royalty Pharma
Veeva Systems
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
RPRX
Royalty Pharma
Market cap
$23.44B
Sector
Healthcare
VEEV
Veeva Systems
Market cap
$26.07B
Sector
Healthcare
Overall winner
Veeva Systems VEEV
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | RPRX | VEEV | Winner |
|---|---|---|---|
| Warren Buffett | 66C | 66B | Tie |
| Benjamin Graham | 84A | 81A | RPRX |
| Philip Fisher | 65C | 77B | VEEV |
| Peter Lynch | 60C | 60C | Tie |
| Joel Greenblatt | 40D | 52C | VEEV |
| Charlie Munger | 68D | 62C | RPRX |
| Terry Smith | 58D | 65D | VEEV |
Side-by-side metrics
| Metric | RPRX | VEEV |
|---|---|---|
| Market cap | $23.44B | $26.07B |
| P/E (TTM) | 27.6x | 28.7x |
| EV/EBIT | 19.9x | 26.9x |
| ROIC (TTM) | 8.43% | 9.48% |
| Gross margin | 99.95% | 75.53% |
| Net margin | 33.91% | 28.44% |
| Revenue CAGR 5y | 0.96% | 14.63% |
| EPS CAGR 5y | 11.83% | 18.76% |
| Debt / Equity | 1.3x | 0.0x |
| Dividend yield | 1.72% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
RPRX leads on
- Dividend yield1.72%vs 0.0%+100%
- EV/EBIT19.9xvs 26.9x+26%
- Gross margin99.95%vs 75.53%+24%
- Net margin33.91%vs 28.44%+16%
VEEV leads on
- Debt / Equity0.0xvs 1.3x+99%
- Revenue CAGR 5y14.63%vs 0.96%+93%
- EPS CAGR 5y18.76%vs 11.83%+37%
- ROIC (TTM)9.48%vs 8.43%+11%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.